TD Cowen analyst Yaron Werber raised the firm’s price target on SpringWorks Therapeutics (SWTX) to $66 from $63 and keeps a Buy rating on the shares. The firm noted FDA aproval for Gomekli is differentiated for adult/ped NF1-PN versus AstraZeneca’s (AZN) Koselugo on safety while also noting the company is in talks with Merck KgaA for what could be in the range of $6-7.5B takeout.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SWTX:
- SpringWorks Therapeutics price target raised to $66 from $63 at TD Cowen
- Springworks Therapeutics Gains FDA Approval for GOMEKLI
- Buy Rating for Springworks Therapeutics Boosted by FDA Approval of GOMEKLI and Strong Market Potential
- SpringWorks Therapeutics confirms FDA approval of Gomekli
- FDA approves SpringWorks’ mirdametinib for adult and pediatric NF1 patients